Cargando…
Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid
Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Person...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890433/ https://www.ncbi.nlm.nih.gov/pubmed/35193475 http://dx.doi.org/10.1080/15384047.2021.2021042 |
_version_ | 1784661638567165952 |
---|---|
author | Kim, Hichul El-Khoury, Victoria Schulte, Nadine Zhan, Tianzuo Betge, Johannes Cousin, Loic Felli, Emanuele Pessaux, Patrick Ogier, Arnaud Opitz, Oliver G Ku, Bosung Ebert, Matthias P Kwon, Yong-Jun |
author_facet | Kim, Hichul El-Khoury, Victoria Schulte, Nadine Zhan, Tianzuo Betge, Johannes Cousin, Loic Felli, Emanuele Pessaux, Patrick Ogier, Arnaud Opitz, Oliver G Ku, Bosung Ebert, Matthias P Kwon, Yong-Jun |
author_sort | Kim, Hichul |
collection | PubMed |
description | Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Personalized functional profiling (PFP), i.e. drug screening, was performed in ex-vivo spheroids obtained from the patient’s liver metastasis to identify potential therapeutic options. The drug screening results revealed cediranib, an antiangiogenic drug, as a hit drug for this patient, from a library of 66 Food and Drug Administration (FDA)-approved and investigational drugs. Based on the PFP results and the reported evidence of clinical efficacy of bevacizumab and capecitabine combination in gastro-intestinal neuroendocrine tumors, this combination was given to the patient. Four months later, the pleural effusion and pleura carcinosis regressed and the liver metastasis did not progress. The patient experienced 2 years of a stable disease under the PFP-guided personalized treatment. |
format | Online Article Text |
id | pubmed-8890433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-88904332022-03-03 Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid Kim, Hichul El-Khoury, Victoria Schulte, Nadine Zhan, Tianzuo Betge, Johannes Cousin, Loic Felli, Emanuele Pessaux, Patrick Ogier, Arnaud Opitz, Oliver G Ku, Bosung Ebert, Matthias P Kwon, Yong-Jun Cancer Biol Ther Bedside-to-Bench Report Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Personalized functional profiling (PFP), i.e. drug screening, was performed in ex-vivo spheroids obtained from the patient’s liver metastasis to identify potential therapeutic options. The drug screening results revealed cediranib, an antiangiogenic drug, as a hit drug for this patient, from a library of 66 Food and Drug Administration (FDA)-approved and investigational drugs. Based on the PFP results and the reported evidence of clinical efficacy of bevacizumab and capecitabine combination in gastro-intestinal neuroendocrine tumors, this combination was given to the patient. Four months later, the pleural effusion and pleura carcinosis regressed and the liver metastasis did not progress. The patient experienced 2 years of a stable disease under the PFP-guided personalized treatment. Taylor & Francis 2022-02-22 /pmc/articles/PMC8890433/ /pubmed/35193475 http://dx.doi.org/10.1080/15384047.2021.2021042 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Bedside-to-Bench Report Kim, Hichul El-Khoury, Victoria Schulte, Nadine Zhan, Tianzuo Betge, Johannes Cousin, Loic Felli, Emanuele Pessaux, Patrick Ogier, Arnaud Opitz, Oliver G Ku, Bosung Ebert, Matthias P Kwon, Yong-Jun Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid |
title | Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid |
title_full | Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid |
title_fullStr | Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid |
title_full_unstemmed | Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid |
title_short | Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid |
title_sort | personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid |
topic | Bedside-to-Bench Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890433/ https://www.ncbi.nlm.nih.gov/pubmed/35193475 http://dx.doi.org/10.1080/15384047.2021.2021042 |
work_keys_str_mv | AT kimhichul personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT elkhouryvictoria personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT schultenadine personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT zhantianzuo personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT betgejohannes personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT cousinloic personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT felliemanuele personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT pessauxpatrick personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT ogierarnaud personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT opitzoliverg personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT kubosung personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT ebertmatthiasp personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid AT kwonyongjun personalizedfunctionalprofilingusingexvivopatientderivedspheroidspointsoutthepotentialofanantiangiogenictreatmentinapatientwithametastaticlungatypicalcarcinoid |